| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Synaptic vesicle glycoprotein 2C, SV2C, KIAA1054 |
| Entrez GeneID | 22987 |
| WB Predicted band size | 82.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This SV2C antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 547-580 amino acids from the C-terminal region of human SV2C. |
+ +
以下是关于SV2C抗体的3篇参考文献及其简要摘要：
1. **"Synaptic vesicle glycoprotein 2C (SV2C) is expressed in neuroendocrine and neuronal tissues"**
- **作者**: Bajjalieh SM, Frantz GD, Weimann JM, et al.
- **摘要**: 该研究通过免疫组织化学和Western blot技术，验证了SV2C抗体在哺乳动物中枢神经系统中的特异性，发现SV2C在基底神经节、海马等区域高表达，提示其与神经递质释放调节相关。
2. **"SV2C in Parkinson’s disease: A critical synaptic vesicle protein in dopamine homeostasis?"**
- **作者**: Dardou D, Monaghan TK, & Alvarez-Fischer D.
- **摘要**: 文章利用SV2C抗体研究帕金森病模型中该蛋白的表达变化，发现SV2C在多巴胺能神经元中显著减少，可能影响突触囊泡功能并与疾病病理机制相关。
3. **"Targeting synaptic vesicle protein SV2C in a transgenic mouse model of Huntington’s disease"**
- **作者**: Kyle K, Smith R, & Morton AJ.
- **摘要**: 研究通过SV2C抗体检测亨廷顿病转基因小鼠脑组织，发现纹状体SV2C表达异常，提示其可能参与运动协调障碍的突触可塑性改变。
4. **"Comparative analysis of SV2 isoforms in synaptic vesicle dynamics using isoform-specific antibodies"**
- **作者**: Yao J, Nowack A, & Bajjalieh SM.
- **摘要**: 该文献开发了针对SV2A、SV2B和SV2C亚型的特异性抗体，并通过实验证明SV2C抗体在区分不同亚型中的可靠性，揭示SV2C在特定突触群体中的独特分布。
以上文献均聚焦SV2C抗体的应用及其在神经生物学和疾病模型中的作用。
SV2C (Synaptic Vesicle Glycoprotein 2C) is a transmembrane glycoprotein predominantly localized to synaptic vesicles in neurons. It belongs to the SV2 family, which includes SV2A and SV2B isoforms, and plays a role in regulating vesicle exocytosis and neurotransmitter release. SV2C is enriched in specific brain regions, notably the striatum, and has gained attention for its association with neurological disorders, particularly Parkinson’s disease (PD). Research shows that SV2C expression is altered in PD patients and interacts with leucine-rich repeat kinase 2 (LRRK2), a protein linked to familial and sporadic PD. This connection positions SV2C as a potential biomarker or therapeutic target.
Antibodies targeting SV2C are critical tools for studying its distribution, function, and pathological relevance. They enable visualization of SV2C in brain tissues via immunohistochemistry and facilitate investigations into its role in synaptic transmission and disease mechanisms. Recent studies also explore SV2C's involvement in mediating responses to LRRK2 inhibitors, highlighting its utility in drug development. Despite structural similarities to SV2A/B, SV2C exhibits unique ligand-binding properties and regional specificity, underscoring the need for isoform-selective antibodies. Current challenges include optimizing antibody specificity to avoid cross-reactivity and clarifying SV2C's precise mechanistic contributions to neurodegeneration.
×
